The rising incidence and prevalence of cancer and disorder may be a key factor supporting market growth. Most cases are often prevented through early detection and treatment; medicine plays a big role in these areas.
As medicine plays a big role in disease diagnosis and treatment, the rising prevalence of those diseases is predicted to drive the expansion of the medicine market during the forecast period.
The expiry of a radiopharmaceutical primarily depends on the half-life of the radioisotope and therefore the content of the radionuclide.
However, the non-utilization of radioisotopes within the prescribed time period causes radiation and chemical decomposition, reducing radiochemical purity to an unacceptable form, which can prove fatal during diagnosis and therapy; these factors are hampering the market growth.
Covid-19 Impact on Nuclear Medicine/Radiopharmaceuticals Market:
In addition, this Global Market study offers an thorough analysis of this COVID-19 pandemic impact on the market growth and its influence on the long run growth of the worldwide Market. The recently published report demonstrates the elevation within the demand for the healthcare sector. The healthcare manufacturers have experienced future also as short term effect which incorporates supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption might be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and makers to the limit. In addition to this, panic conditions have already spurred the demand for several healthcare products and services which are discussed intimately during this report. Moreover, the impact of this pandemic on overall market revenue for rock bottom year 2020 and its projection up to 2027 is provided intimately during this report.
Nuclear Medicine/Radiopharmaceuticals Market Segment Overview
By type, Beta emitters held the most important share of the marketplace for medicine in 2019 due to less damage to surrounding cells, low energy levels, and travel long distance.
By Application, The oncology segment accounted for the best market share in 2018 because of increase in number of cancer cases and use of F-18 isotope. The top user segment has been segmented into research institutes, hospitals, diagnostic centers, et al.
By Industry Verticals, Cardiology is predicted to be the fastest growing segment during the forecast period due to the low cost of techniques and high adoption rate. Therefore, key players are that specialize in the event of latest diagnostic techniques to combat cardiovascular diseases.
Market Analysis, Insights and Forecast – By Type
· Therapeutic
· Alpha Emitters
· Beta Emitters
· Brachytherapy Isotopes
· Diagnostic
· PET Radiopharmaceuticals
· SPECT Radiopharmaceuticals
Market Analysis, Insights and Forecast – By Application
· Cardiology
· Oncology
· Thyroid
· Neurology
· Others
Market Analysis, Insights and Forecast – By Industry Verticals
· Research Institutes
· Hospitals
· Diagnostic Centers
· Others
Nuclear Medicine/Radiopharmaceuticals Market Regional Overview
Region-wise, in terms of regions, North America accounted for the biggest share of the market in 2019, followed by Europe and therefore the Asia Pacific. North America’s leading position is primarily because of the rising pet expenditure, the growing population of companion animals, and therefore the increasing consumption of animal-derived food products, thus encouraging the R&D activities, thereby boosting the market growth.
Nuclear Medicine/Radiopharmaceuticals Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Nuclear Medicine/Radiopharmaceuticals Market Competitor overview
Some key developments and strategies adopted by manufacturers in the Nuclear Medicine/Radiopharmaceuticals are highlighted below.
· In 2017, Royal Philips launched CardioMD IV, that a cardiac SPECT solution to deliver improved workflow for cardiac imaging at a lower cost.
Nuclear Medicine/Radiopharmaceuticals Market, Key Players
· Cardinal Health
· GE Healthcare
· Curium
· Lantheus Medical Imaging
· Bayer AG
· Bracco Imaging
· Eczacýbaþý-Monrol Nuclear Products
· Nordion
· Advanced Accelerator Applications
· NTP Radioisotopes
· JSC Isotope
· NorthStar Medical Radioisotopes
· Eckert & Ziegler
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Nuclear Medicine/Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type
- 5.2.1. Therapeutic
- 5.2.2. Alpha Emitters
- 5.2.3. Beta Emitters
- 5.2.4. Brachytherapy Isotopes
- 5.2.5. Diagnostic
- 5.2.6. PET Radiopharmaceuticals
- 5.2.7. SPECT Radiopharmaceuticals
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Cardiology
- 5.3.2. Oncology
- 5.3.3. Thyroid
- 5.3.4. Neurology
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By Industry Verticals
- 5.4.1. Research Institutes
- 5.4.2. Hospitals
- 5.4.3. Diagnostic Centers
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East, and Africa
6. North America Nuclear Medicine/Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Type
- 6.2.1. Therapeutic
- 6.2.2. Alpha Emitters
- 6.2.3. Beta Emitters
- 6.2.4. Brachytherapy Isotopes
- 6.2.5. Diagnostic
- 6.2.6. PET Radiopharmaceuticals
- 6.2.7. SPECT Radiopharmaceuticals
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Cardiology
- 6.3.2. Oncology
- 6.3.3. Thyroid
- 6.3.4. Neurology
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By Industry Verticals
- 6.4.1. Research Institutes
- 6.4.2. Hospitals
- 6.4.3. Diagnostic Centers
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Nuclear Medicine/Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Type
- 7.2.1. Therapeutic
- 7.2.2. Alpha Emitters
- 7.2.3. Beta Emitters
- 7.2.4. Brachytherapy Isotopes
- 7.2.5. Diagnostic
- 7.2.6. PET Radiopharmaceuticals
- 7.2.7. SPECT Radiopharmaceuticals
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Cardiology
- 7.3.2. Oncology
- 7.3.3. Thyroid
- 7.3.4. Neurology
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By Industry Verticals
- 7.4.1. Research Institutes
- 7.4.2. Hospitals
- 7.4.3. Diagnostic Centers
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Type
- 8.2.1. Therapeutic
- 8.2.2. Alpha Emitters
- 8.2.3. Beta Emitters
- 8.2.4. Brachytherapy Isotopes
- 8.2.5. Diagnostic
- 8.2.6. PET Radiopharmaceuticals
- 8.2.7. SPECT Radiopharmaceuticals
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Cardiology
- 8.3.2. Oncology
- 8.3.3. Thyroid
- 8.3.4. Neurology
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By Industry Verticals
- 8.4.1. Research Institutes
- 8.4.2. Hospitals
- 8.4.3. Diagnostic Centers
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East, and Africa Nuclear Medicine/Radiopharmaceuticals Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Type
- 9.2.1. Therapeutic
- 9.2.2. Alpha Emitters
- 9.2.3. Beta Emitters
- 9.2.4. Brachytherapy Isotopes
- 9.2.5. Diagnostic
- 9.2.6. PET Radiopharmaceuticals
- 9.2.7. SPECT Radiopharmaceuticals
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Cardiology
- 9.3.2. Oncology
- 9.3.3. Thyroid
- 9.3.4. Neurology
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By Industry Verticals
- 9.4.1. Research Institutes
- 9.4.2. Hospitals
- 9.4.3. Diagnostic Centers
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Cardinal Health
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. GE Healthcare
- 10.6. Curium
- 10.7. Lantheus Medical Imaging
- 10.8. Bayer AG
- 10.9. Bracco Imaging
- 10.10. Eczacýbaþý-Monrol Nuclear Products
- 10.11. Nordion
- 10.12. Advanced Accelerator Applications
- 10.13. NTP Radioisotopes
- 10.14. JSC Isotope
- 10.15. NorthStar Medical Radioisotopes
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
